Savara’s (SVRA) In-Line Rating Reiterated at Evercore ISI

Evercore ISI reiterated their in-line rating on shares of Savara (NASDAQ:SVRA) in a research note issued to investors on Wednesday morning, Marketbeat reports. Evercore ISI currently has a $5.00 price target on the stock, down from their prior price target of $7.00.

A number of other research firms have also commented on SVRA. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Savara in a report on Tuesday, October 8th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Price Performance

Savara stock opened at $2.98 on Wednesday. The business’s 50-day simple moving average is $3.91 and its 200 day simple moving average is $4.20. The company has a quick ratio of 11.31, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $511.43 million, a price-to-earnings ratio of -6.93 and a beta of 1.02. Savara has a 12-month low of $2.83 and a 12-month high of $5.70.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). As a group, research analysts anticipate that Savara will post -0.44 earnings per share for the current year.

Institutional Trading of Savara

Several hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC increased its holdings in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after acquiring an additional 746,407 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after purchasing an additional 148,673 shares during the period. Swiss National Bank bought a new stake in Savara during the 1st quarter worth approximately $732,000. Frazier Life Sciences Management L.P. raised its holdings in Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after buying an additional 4,157,385 shares during the period. Finally, Nantahala Capital Management LLC lifted its stake in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.